| Fallopian Tube Endometrioid Tumor studied in …STUDIED_INderived10 of 42show all (up to 200) |
|---|
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 42 trials mapped (20 active) | — | — | Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 42 trials mapped (20 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 42 trials mapped (20 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04575935Phase 3 · recruiting Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial · condition mapped ONTOLOGY_EXACT · 42 trials mapped (20 active) | — | — | Fallopian Tube Endometrioid Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 42 trials mapped (20 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04034927Phase 2 · active not recruiting Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 42 trials mapped (20 active) | — | — | Fallopian Tube Endometrioid Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02068794Phase 1/Phase 2 · active not recruiting MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 42 trials mapped (20 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05415709early Phase 1 · active not recruiting Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 42 trials mapped (20 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 42 trials mapped (20 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 42 trials mapped (20 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |